U.S. Markets closed

NanoViricides reports orphan drug application made to EMA for DengueCide

NanoViricides announced that the European associates of the consulting firm Cote´ Orphan Consulting, on behalf of NanoViricides, have submitted an Orphan Drug Application to the European Medicines Agency for DengueCide, a drug candidate for the treatment of dengue and dengue hemorrhagic fever.